DIRECT ISSUE 2025
Stayble Therapeutics AB has carried out a directed issue of a total of 4 212 963 units, where each unit consists of three newly issued shares and two warrants of series TO3 in the Company, corresponding to a total of 12 638 889 shares and 8 425 926 warrants of series TO3.
Through the direct issue, the Company was thus provided with approximately 4,55 million SEK before deductions for transaction costs, and if all the attached warrants of series TO3 are used for the subscription of shares in the Company, the Company will, depending on the subscription price upon exercise of the warrants, be provided with approximately 2,1 to 4,2 million SEK before deductions for transaction costs.
For more information, see the following link (in Swedish):
https://staybletherapeutics.com/sv/investerare/riktad-emission-2025/
